• 1. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 2. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 3. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 4. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 5. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526

Comprehensive Guide to 2-(3,5-Dimethylpiperidin-1-yl)ethanamine (CAS No. 876716-58-4): Properties, Applications, and Market Insights

2-(3,5-Dimethylpiperidin-1-yl)ethanamine (CAS No. 876716-58-4) is a specialized organic compound that has garnered significant attention in pharmaceutical and chemical research. This piperidine derivative is known for its unique structural properties, making it a valuable intermediate in the synthesis of various bioactive molecules. Researchers and industry professionals often search for "2-(3,5-Dimethylpiperidin-1-yl)ethanamine uses" or "CAS 876716-58-4 suppliers," highlighting its growing relevance in modern chemistry.

The molecular structure of 2-(3,5-Dimethylpiperidin-1-yl)ethanamine features a piperidine ring substituted with two methyl groups at the 3 and 5 positions, along with an ethanamine side chain. This configuration contributes to its versatility in drug discovery, particularly in the development of central nervous system (CNS) therapeutics. Recent trends show increased interest in "piperidine-based drug candidates" and "amine derivatives in medicinal chemistry," positioning this compound as a key player in innovative research.

In pharmaceutical applications, 2-(3,5-Dimethylpiperidin-1-yl)ethanamine serves as a crucial building block for neurologically active compounds. Its structural motif is frequently explored in the design of receptor modulators and enzyme inhibitors. The compound's potential in addressing neurodegenerative disorders aligns with current healthcare priorities, as evidenced by rising searches for "new Alzheimer's disease treatments" and "Parkinson's disease research chemicals."

The synthesis of 2-(3,5-Dimethylpiperidin-1-yl)ethanamine typically involves reductive amination or nucleophilic substitution reactions, with process optimization being a frequent topic in chemical forums. Manufacturers focusing on "high-purity amine compounds" and "custom chemical synthesis" services often highlight this compound in their catalogs. Analytical techniques such as HPLC, NMR, and mass spectrometry are essential for quality control, addressing the industry demand for "chemical characterization methods."

From a commercial perspective, the market for 2-(3,5-Dimethylpiperidin-1-yl)ethanamine reflects the broader growth in pharmaceutical intermediates. Global suppliers are responding to inquiries about "bulk quantities of CAS 876716-58-4" and "GMP-compliant chemical manufacturing." The compound's stability and solubility profile make it suitable for various formulation developments, particularly in preclinical research settings.

Recent advancements in green chemistry have influenced the production processes for 2-(3,5-Dimethylpiperidin-1-yl)ethanamine, with researchers exploring catalytic methods and solvent-free conditions. These developments respond to the increasing search volume for "environmentally friendly chemical synthesis" and "green pharmaceutical intermediates." The compound's role in sustainable drug development aligns with global initiatives in green technology.

Quality standards for 2-(3,5-Dimethylpiperidin-1-yl)ethanamine are strictly maintained, with specifications typically including ≥98% purity and controlled levels of residual solvents. Analytical certificates often accompany commercial samples, addressing the pharmaceutical industry's need for "fully characterized research chemicals." Storage recommendations generally suggest cool, dry conditions in airtight containers to maintain stability.

The research community continues to explore novel derivatives of 2-(3,5-Dimethylpiperidin-1-yl)ethanamine, particularly in structure-activity relationship studies. This aligns with current scientific interests in "molecular modification strategies" and "lead compound optimization." The compound's structural flexibility makes it an attractive scaffold for medicinal chemistry applications.

Regulatory aspects of 2-(3,5-Dimethylpiperidin-1-yl)ethanamine vary by region, with most jurisdictions classifying it as a research chemical rather than a controlled substance. This distinction is important for laboratories searching for "non-scheduled chemical intermediates" or "unrestricted research compounds." Proper documentation and material safety data sheets are essential for compliance with laboratory safety protocols.

Future prospects for 2-(3,5-Dimethylpiperidin-1-yl)ethanamine appear promising, particularly in the context of personalized medicine and targeted drug delivery systems. The compound's potential applications in bioconjugation and prodrug development are areas of active investigation, responding to growing interest in "advanced drug formulation techniques" and "novel drug delivery mechanisms."

• 775288-27-2(1H-1,4-Diazepine,hexahydro-1-methyl-4-(4-piperidinylmethyl)-)
• 1293115-59-9(2-(4-Dimethylaminomethyl-piperidin-1-yl)-ethylamine)
• 1353948-21-6(N*1*-Methyl-N*1*-(1-methyl-piperidin-4-ylmethyl)-ethane-1,2-diamine)
• 496808-04-9(1-(1-Methylpiperidin-4-yl)methylpiperazine)
• 775288-25-0(1-Ethyl-4-(piperidin-4-ylmethyl)piperazine)
• 154517-69-8(1,4-Diazabicyclo[4.3.1]decane(9CI))
• 735262-46-1(1-methyl-4-[(piperidin-4-yl)methyl]piperazine)
• 1353951-95-7(N*1*-Ethyl-N*1*-(1-methyl-piperidin-4-ylmethyl)-ethane-1,2-diamine)
• 67990-20-9(1,1'-ethylenebis[3-methylpiperidine])
• 85723-75-7(2-(3-Methylpiperidin-1-yl)ethanamine)